Amyotrophic Lateral Sclerosis

A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Also Known As:

Lou Gehrig's Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis; Lou Gehrig Disease; ALS (Amyotrophic Lateral Sclerosis); Amyotrophic Lateral Sclerosis With Dementia; Amyotrophic Lateral Sclerosis, Guam Form; Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1; Amyotrophic lateral sclerosis, Parkinsonism/Dementia complex of Guam; Dementia With Amyotrophic Lateral Sclerosis; Gehrig's Disease; Guam Form of Amyotrophic Lateral Sclerosis; Lou-Gehrigs Disease; Disease, Lou-Gehrigs; Gehrig Disease; Gehrigs Disease; Lateral Scleroses, Amyotrophic; Sclerosis, Amyotrophic Lateral

Nervous System Diseases: 6158
- Neurodegenerative Diseases: 16953
  - Motor Neuron Disease: 1250
    - Amyotrophic Lateral Sclerosis: 5913
  - TDP-43 Proteinopathies: 129
    - Amyotrophic Lateral Sclerosis: 5913
- Central Nervous System Diseases: 1649
  - Spinal Cord Diseases: 2168
    - Amyotrophic Lateral Sclerosis: 5913
- Neuromuscular Diseases: 1068
  - Motor Neuron Disease: 1250
    - Amyotrophic Lateral Sclerosis: 5913
Nutritional and Metabolic Diseases: 2
- Metabolic Diseases: 3200
  - Proteostasis Deficiencies: 234
    - TDP-43 Proteinopathies: 129
      - Amyotrophic Lateral Sclerosis: 5913

G B Miles Selected Research

G B Miles Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure